JOHANNESBURG: Two doses of Pfizer-BioNTech's COVID-19 vaccine appear to have given 70% protection against hospitalisation in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday, as the country battles a spike in infections linked to the new variant.
The study released by South Africa's largest private health insurance administrator, Discovery Health, was based on more than 211,000 positive COVID-19 test results from Nov. 15 to Dec. 7, around 78,000 of which were attributed to Omicron.
The 78,000 results are not confirmed Omicron cases, meaning the study is not able to make conclusive findings about the variant labelled "of concern" by the World Health Organization.
South African scientists have so far confirmed around 550 Omicron sequences, with the variant accounting for 78% of sequences from November, more than the previously dominant Delta variant.
South Africa alerted the world to Omicron late last month, triggering alarm that it could cause another surge in global infections, and leading to the imposition of travel restrictions on southern Africa. South Africa's daily infections have since risen to around 20,000 in recent days.
Based on analysis by Discovery's clinical research and actuarial teams, and in collaboration with South Africa's Medical Research Council (SAMRC), the study calculated that two doses of Pfizer-BioNTech offered 70% protection against hospitalisation compared with the unvaccinated during the recent surge in cases and 33% protection against infection.
It said this represents a drop from 80% protection against infection and compares with above 90% efficacy against hospital admission during South Africa's outbreak of the Delta variant, which is the globally dominant variant and considered to be the most infectious to emerge during the pandemic.
Discovery cautioned that the study's findings should be considered preliminary.
But Glenda Gray, SAMRC president, said it was important that the Pfizer-BioNTech vaccine appeared to be offering good protection against severe disease and hospitalisation as a highly transmissible new variant circulates.
"We are extremely encouraged by the results," she said in a statement.
The analysis also shows protection against hospital admission is maintained across all ages, in people from 18 to 79 years, with slightly lower levels of protection for the elderly.
Protection against admission is also consistent across a range of chronic illnesses including diabetes, hypertension, hypercholesterolemia, and other cardiovascular diseases.
South Africa is using the Pfizer-BioNTech and Johnson & Johnson (JNJ.N) vaccines in its COVID-19 immunisation campaign, with more than 20 million Pfizer doses administered so far.
It concluded that there was a higher risk of reinfection during the fourth wave than during previous waves and that the risk of hospitalisation among adults diagnosed with COVID-19 was 29% lower than during the country's first wave early last year.
Children appeared to have a 20% higher risk of hospital admission with complications during the fourth wave than during the first, despite a very low absolute incidence, it said.
Reuters
Tue Dec 14 2021
A healthcare worker administers the Pfizer coronavirus disease (COVID-19) vaccine to a man, amidst the spread of the SARS-CoV-2 variant Omicron, in Johannesburg, South Africa, December 9, 2021. - REUTERS/Sumaya Hisham/File Photo
SUKMA 2024: Sepak takraw wanita mungkin digugurkan
Sepak takraw wanita berpasukan berkemungkinan akan digugurkan daripada senarai acara temasya Sukan Malaysia (SUKMA) 2024 berikutan jumlah penyertaan kurang daripada jumlah minimum yang ditetapkan.
10 Berita Pilihan - (16 Julai 2024)
Antara pelbagai berita dalam dan luar negara yang disiarkan di Astro AWANI, berikut adalah yang paling menjadi tumpuan sepanjang hari ini.
Enam rakyat Vietnam ditemukan maut di sebuah hotel di Bangkok
Enam orang ditemukan maut di sebuah hotel di Bangkok, Thailand pada Selasa laporan media tempatan yang memetik polis Bangkok.
AWANI 7:45 [16/07/2024] - Suspek dibawa ke lokasi | Selamat tinggal rakyat Malaysia | Harimau Malaya hilang taring?
- Polis sahkan suspek bunuh Kartini anggota polis.
- Pan-Gon enggan dedah punca letak jawatan.
- Faisal Halim sedih mentor Pan-Gon undur diri.
- Pakai reben putih di Parlimen, tak salah.
- Pan-Gon enggan dedah punca letak jawatan.
- Faisal Halim sedih mentor Pan-Gon undur diri.
- Pakai reben putih di Parlimen, tak salah.
Najib fail permohonan di mahkamah rayuan cabar Titah Adendum
Berdasarkan sistem e-filing mahkamah, rayuan itu telah ditetapkan untuk pengurusan kes pada 7 Oktober ini.
Pangsapuri mewah bernilai RM1 juta menanti pemenang emas Olimpik
Hannah Yeoh berkata Jawatankuasa RTG telah menerima tawaran daripada pemaju hartanah, Top Residency, yang berminat untuk menghadiahkan pemenang pingat emas pertama.
E-sukan harus dijadikan kepentingan sehingga ke peringkat lebih tinggi
Kerajaan juga harus wujudkan sebuah dasar yang jelas supaya kepentingan e-sukan ini mampu diperkembangkan ke masa hadapan.
Kerajaan pandang serius penularan ideologi liberalism, pluralism
Kerajaan sentiasa memandang serius terhadap penularan ideologi dan aliran pemikiran yang bercanggah dengan ajaran Islam seperti ideologi liberalism dan pluralism agama.
Tidak dapat tidak, atlet RTG mesti bawa pulang emas - MOM
Atlet di bawah projek Road To Gold (RTG) tidak mempunyai pilihan selain memenangi emas yang diidam-idamkan Malaysia pada Sukan Olimpik 2024 di Paris.
KEDA peruntuk RM3.37 juta tahun ini bagi keterjaminan makanan
Lembaga Kemajuan Wilayah Kedah (KEDA) memperuntukkan RM3.37 juta pada tahun ini bagi memastikan keterjaminan makanan negara.
Vaksin COVID-19: FDA lulus penuh Pfizer untuk usia 12-15 tahun
Vaksin itu sebelum ini mendapat kelulusan kecemasan bagi kumpulan umur berkenaan sejak Mei 2021.
Vaksin COVID-19: Kanak-kanak bawah lima tahun terima suntikan
Rata-rata menyambut baik keputusan tersebut dengan ibu-bapa membawa anak-anak mereka mendapatkan vaksinasi.
Vaksin COVID-19: AS mula suntik kanak-kanak bawah 5 tahun 21 Jun ini
Kerajaan persekutuan akan menyediakan 10 juta vaksin kepada pihak berkuasa negeri dan tempatan untuk memulakan vaksinasi meluas.
Vaksin COVID-19: Pfizer didapati selamat untuk kanak-kanak bawah 5 tahun
Berdasarkan ujian klinikal terbaharu, keberkesanan vaksin bagi tiga dos adalah pada kadar 80.3 peratus.
COVID-19 : Vaksin mRNA China sasar Omicron jalani ujian di UAE
Syarikat Suzhou Abogen Biosciences Co Ltd menyertai Pfizer-BioNTech dan Moderna dalam menguji calon vaksin yang diubah suai secara khusus menentang Omicron.
Vaksin COVID-19: Dos penggalak tingkat perlindungan terhadap Omicron - Pfizer
Analisis serum darah 30 kanak-kanak yang menerima dos penggalak menunjukkan peningkatan 36 kali ganda dalam antibodi peneutral Omicron.
Pfizer, BioNTech mohon kebenaran FDA untuk dos penggalak kedua
FDA berkata ia akan menyemak permintaan Pfizer dan BioNTech "secepat mungkin menggunakan pendekatan menyeluruh dan berasaskan sains."
Ibu bapa perlu sasarkan kerisauan kepada jangkitan COVID-19, bukan vaksin
Rata-rata ibu bapa memberi alasan tidak mahu anak mereka diperlakukan seperti "tikus makmal".
PICKids Pahang bermula Isnin
Buat permulaan hanya satu jenis vaksin sahaja yang ditawarkan iaitu Corminaty (Pfizer-BioNTech) dos kanak-kanak.
PICKids: 517,107 kanak-kanak daftar terima vaksin setakat 1 Feb - Khairy
Selangor mencatatkan pendaftaran paling tinggi iaitu lebih 131,000 orang, diikuti Johor (81,400) dan Wilayah Persekutuan Kuala Lumpur.